Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020–2024
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00658-25 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Clémentine de La Porte des Vaux und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Univer…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, Immunocompromised Host, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunocompromised patients (ICPs) infected with SARS-CoV-2 are at higher risk of severe illness. Some experience persistent viral shedding beyond eight weeks, which is associated with increased mortality and invasive fungal infections. However, data on the clinical profile, treatment impact, and standardized management for these patients remain limited. We conducted a retrospective cohort study at Groupe Hospitalier Paris Centre between March 1, 2020, and February 10, 2024. We assessed symptomatic ICPs with persistent SARS-CoV-2 shedding (>8 weeks), analyzing clinical progression, time to viral clearance, and emergence of resistance mutations in relation to treatment regimens. Fifty-three patients were included: 53% were solid organ transplant (SOT) recipients, 42% had hematological malignancies (HMs), and 5% had other immunosuppressive conditions. Severe infections occurred in 32%, 91% required hospitalization, and 17% ( n = 9) presented invasive mold infections. SOT recipients achieved clinical cure faster than HM patients ( P < 0.01). Patients treated with direct antivirals showed significantly faster viral clearance ( P = 0.03) than those treated with monoclonal antibodies (mAbs) or convalescent plasma. No resistance mutations emerged against remdesivir or nirmatrelvir/ritonavir. However, 54% of viral strains showed initial or acquired spike protein resistance to mAbs. Direct antiviral therapies, particularly remdesivir and nirmatrelvir/ritonavir, appear safe and effective in promoting faster viral clearance and clinical recovery in ICPs with persistent symptomatic SARS-CoV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious and Tropical Diseases, Hôpital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), IHU Imagine, Université Paris Cité, Paris, France.
- Department of Virology, Hôpital Necker Enfants Malades, APHP, Université Paris Cité, Paris, France.
- National Reference Center for Respiratory Viral Infections, Institut Pasteur, Université Paris Cité, Paris, France.
- Department of Nephrology and Kidney Transplantation, European Hospital George Pompidou, APHP, Université Paris Cité, Paris, France.
- Intensive Care Unit, Hospital Necker-Enfants Malades, APHP, Université Paris Cité, Paris, France.
- Department of Nephrology and Kidney Transplantation, Hospital Necker-Enfants Malades, APHP, Université Paris Cité, Paris, France.
ORCID-Profile: Clémentine de La Porte des Vaux, Kevin Da Silva, Cléa Melenotte
Zitieren
APA
de La Porte des Vaux, C., Veyrenche, N., Silva, K. D., Chavarot, N., Burgard, M., Paccoud, O., Runyo, F., Garzaro, M., Rouzaud, C., Serris, A., Vimpere, D., Anglicheau, D., Mouthon, L., Hermine, O., Rameix-Welti, M. A., Lanternier, F., Lortholary, O., & Melenotte, C. (2025). Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020–2024. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00658-25
Vancouver
de La Porte des Vaux C, Veyrenche N, Silva KD, Chavarot N, Burgard M, Paccoud O, et al. Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020–2024. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00658-25
BibTeX
@article{deLaPortedesVaux2025,
author = {de La Porte des Vaux, Clémentine and Veyrenche, Nicolas and Silva, Kevin Da and Chavarot, Nathalie and Burgard, Marianne and Paccoud, Olivier and Runyo, Florence and Garzaro, Margaux and Rouzaud, Claire and Serris, Alexandra and Vimpere, Damien and Anglicheau, Dany and Mouthon, Luc and Hermine, Olivier and Rameix-Welti, Marie-Anne and Lanternier, Fanny and Lortholary, Olivier and Melenotte, Cléa},
title = {Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020–2024},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00658-25}
}
EUVIMED